|
|
|
|
|
The Siemens Serum HER-2/neu test accurately monitors disease progression in metastatic breast cancer patients whose initial value is greater than 15 ng/mL, providing information about disease progression and effectiveness of treatment. |
|
Through our proud sponsorship of Imaginis, Medtronic is dedicated to providing comprehensive information and service to improve and advance women's health. |
Updated: July 18, 2009 | |
Imaginis.com suscribes to the HONcode principles of the Health on the Net Foundation.
Copyright 1997-2009 Imaginis Corporation. All rights reserved. Imaginis® is a registered service mark of Imaginis Corporation, a health services company. All other trademarks and copyrights are property of their respective owners. Note: Use of this online service is subject to the disclaimer and the terms and conditions contained herein. Information found within the Imaginis.com website or in other sites linked to from Imaginis.com is provided for educational purposes only and is not intended to be used as a substitute for diagnosis and treatment by a medical doctor. Imaginis does not endorse and has no responsibility for the content of any other sites listed on Imaginis.com, and provides links and references merely as a convenience to its users. Seek immediate medical attention if your condition is urgent. Imaginis - The Breast Cancer Resource